Evidence map›Paper›PMID 40643259›Full record

ArticleJournal of clinical microbiology2025

Multicenter evaluation of the QIAstat-Dx Gastrointestinal Panel 2, a multiplex PCR platform for the diagnosis of acute gastroenteritis.

Wendy A Szymczak, Anne Line Engsbro, Jan Gorm Lisby, Juan José González-López, Paul Granato, Nathan Ledeboer, Donna M Wolk, Stephen Young, Daniel D Rhoads, Yvan Caspar and 14 more

Abstract readClinical StudyMulticenter Study
In one paragraph

Article in Journal of clinical microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Impact of the BioFireBMC infectious diseases · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Wendy A SzymczakDepartment of Pathology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA.ORCID 0000-0002-0747-1169
Anne Line EngsbroCopenhagen University Hospital and Hvidovre, Copenhagen, Denmark.
Jan Gorm LisbyCopenhagen University Hospital and Hvidovre, Copenhagen, Denmark.
Juan José González-LópezDepartment of Clinical Microbiology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Paul GranatoLaboratory Alliance of Central, Liverpool, New York, USA.ORCID 0000-0002-5068-1137
Nathan LedeboerDepartment of Pathology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Donna M WolkGeisinger Diagnostic Medicine Institute, Danville, Pennsylvania, USA.ORCID 0000-0003-2828-5135
Stephen YoungTriCore Reference Laboratories, Albuquerque, New Mexico, USA.
Daniel D RhoadsDepartment of Pathology and Laboratory Medicine, Cleveland Clinic, Cleveland, Ohio, USA.ORCID 0000-0002-7636-5191
Yvan CasparLaboratoire de Bacteriologie - Hygiene Hospitaliere, CHU Grenoble Alpes, La Tronche, Auvergne-Rhône-Alpes, France.ORCID 0000-0002-8332-9383
Lisa SteedMedical University of South Carolina, Charleston, South Carolina, USA.
Romney HumphriesVanderbilt University Medical Center, Nashville, Tennessee, USA.ORCID 0000-0002-6568-156X
Christopher BielefeldtChristus Health, Beaumont, Texas, USA.
Markus HermanowskiLabor Berlin - Charite Vivantes GmbH, Berlin, Germany.
Juana L de DiegoLabor Berlin - Charite Vivantes GmbH, Berlin, Germany.
Hendrik LeibhanLabor Berlin - Charite Vivantes GmbH, Berlin, Germany.
Pau BoherSTAT-Dx Life, S.L. (a QIAGEN Company), Baldiri Reixac, Barcelona, Spain.
Carla CamprubíSTAT-Dx Life, S.L. (a QIAGEN Company), Baldiri Reixac, Barcelona, Spain.
Maria OrthodoxouQIAGEN Manchester Ltd, Citylabs 2.0, Manchester, England, United Kingdom.
Ester SalaSTAT-Dx Life, S.L. (a QIAGEN Company), Baldiri Reixac, Barcelona, Spain.ORCID 0000-0002-2376-6231
Sarah JohnsonQIAGEN Manchester Ltd, Citylabs 2.0, Manchester, England, United Kingdom.
Martí Juanola-FalgaronaSTAT-Dx Life, S.L. (a QIAGEN Company), Baldiri Reixac, Barcelona, Spain.ORCID 0000-0002-4566-7154
Davide ManisseroQIAGEN Manchester Ltd, Citylabs 2.0, Manchester, England, United Kingdom.
Johanna BialasLabor Berlin - Charite Vivantes GmbH, Berlin, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The QIAstat-Dx Gastrointestinal Panel 2 (GI2 Panel) is a sample-to-answer multiplex PCR instrument that can detect 17 targets in a run time of about 80 minutes. The performance of the QIAstat-Dx GI2 Panel was evaluated by testing 1,939 prospective, 119 prospectively collected and then archived positive clinical samples and 750 retrospective clinical specimens across 13 sites in Europe and the United States. Specimens tested included bulk stool samples preserved in modified Cary-Blair transport medium. For most targets, results were compared to those of the FilmArray GI panel (13/17), and discordant results were adjudicated with a third assay. For the remaining targets (4/17), a composite comparator method was used, which included three comparator assays for each target. Before discordant resolution, the QIAstat-Dx GI2 Panel positive percent agreement (PPA) was 95% or greater for 5/17 targets (

Indexed as

GastroenteritisMolecular Diagnostic TechniquesMultiplex Polymerase Chain ReactionAdolescentAdultAgedAged, 80 and overBacteriaChildChild, PreschoolEuropeFecesFemaleHumansInfantMalediarrheagastrointestinal infectiongastrointestinal panelmultiplex PCRQIAstat-Dxsyndromic testing

Identifiers

PMID40643259
PMCPMC12345276

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.